SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Henry Niman who wrote (2357)10/16/1997 10:36:00 AM
From: margie   of 6136
 
Viracept's market share has increased to 28% from 26%, for total scrips, for September. Viracept's market share for new scrips has now climbed to 29% from 27%. Wholesale orders look stronger than ever.

Update from Hamburg on SPICE: Study of Protease Inhibitors in Combination in Europe.
Used Fortovase -soft gel saquinavir, Viracept and 2 rti's.
Study used naive and treatment experienced patients.
Response rates were higher in the 4 drug group, than the 2 drug group.
This combination produced a 90% response rate by 12 weeks.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News